These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22712693)

  • 1. The importance of preclinical trial timing - a potential reason for the disconnect between mouse studies and human clinical trials in ALS.
    Kong Q; Carothers S; Chang Y; Glenn Lin CL
    CNS Neurosci Ther; 2012 Sep; 18(9):791-3. PubMed ID: 22712693
    [No Abstract]   [Full Text] [Related]  

  • 2. Minocycline for patients with ALS.
    Carrì MT
    Lancet Neurol; 2008 Feb; 7(2):118-9; author reply 120-1. PubMed ID: 18207105
    [No Abstract]   [Full Text] [Related]  

  • 3. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS.
    Zhang W; Narayanan M; Friedlander RM
    Ann Neurol; 2003 Feb; 53(2):267-70. PubMed ID: 12557297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis.
    Kriz J; Nguyen MD; Julien JP
    Neurobiol Dis; 2002 Aug; 10(3):268-78. PubMed ID: 12270689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis.
    Pitzer C; Krüger C; Plaas C; Kirsch F; Dittgen T; Müller R; Laage R; Kastner S; Suess S; Spoelgen R; Henriques A; Ehrenreich H; Schäbitz WR; Bach A; Schneider A
    Brain; 2008 Dec; 131(Pt 12):3335-47. PubMed ID: 18835867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop.
    Ludolph AC; Bendotti C; Blaugrund E; Hengerer B; Löffler JP; Martin J; Meininger V; Meyer T; Moussaoui S; Robberecht W; Scott S; Silani V; Van Den Berg LH;
    Amyotroph Lateral Scler; 2007 Aug; 8(4):217-23. PubMed ID: 17653919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical research: Make mouse studies work.
    Perrin S
    Nature; 2014 Mar; 507(7493):423-5. PubMed ID: 24678540
    [No Abstract]   [Full Text] [Related]  

  • 8. [Minocycline for the treatment of amyotrophic lateral sclerosis: neuroprotector or neurotoxin? Reflections on another failure of translational medicine].
    Gámez J
    Neurologia; 2008 Oct; 23(8):484-93. PubMed ID: 18802797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lost in translation: treatment trials in the SOD1 mouse and in human ALS.
    Benatar M
    Neurobiol Dis; 2007 Apr; 26(1):1-13. PubMed ID: 17300945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase.
    Kriz J; Gowing G; Julien JP
    Ann Neurol; 2003 Apr; 53(4):429-36. PubMed ID: 12666110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratracheal co-administration of antioxidants and ceftriaxone reduces pulmonary injury and mortality rate in an experimental model of sepsis.
    Galvão AM; Wanderley MS; Silva RA; Filho CA; Melo-Junior MR; Silva LA; Streck EL; Dornelas de Andrade AF; Souza Maia MB; Barbosa de Castro CM
    Respirology; 2014 Oct; 19(7):1080-7. PubMed ID: 25124169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of trientine or ascorbate alone compared to that of the combined treatment with these two agents in familial amyotrophic lateral sclerosis model mice.
    Nagano S; Fujii Y; Yamamoto T; Taniyama M; Fukada K; Yanagihara T; Sakoda S
    Exp Neurol; 2003 Feb; 179(2):176-80. PubMed ID: 12618124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis.
    Tanaka K; Kanno T; Yanagisawa Y; Yasutake K; Hadano S; Yoshii F; Ikeda JE
    Exp Neurol; 2011 Nov; 232(1):41-52. PubMed ID: 21867702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selecting promising ALS therapies in clinical trials.
    Glass JD; Benatar M; Polak M
    Neurology; 2007 May; 68(18):1545-6; author reply 1546. PubMed ID: 17470765
    [No Abstract]   [Full Text] [Related]  

  • 15. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment.
    Weishaupt JH; Bartels C; Pölking E; Dietrich J; Rohde G; Poeggeler B; Mertens N; Sperling S; Bohn M; Hüther G; Schneider A; Bach A; Sirén AL; Hardeland R; Bähr M; Nave KA; Ehrenreich H
    J Pineal Res; 2006 Nov; 41(4):313-23. PubMed ID: 17014688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapeutic targets in neurodegenerative diseases: lessons from amyotrophic lateral sclerosis.
    Appel SH; Beers DR; Henkel JS; Zhao W
    Curr Neurol Neurosci Rep; 2008 Sep; 8(5):353-5. PubMed ID: 18713569
    [No Abstract]   [Full Text] [Related]  

  • 17. Minocycline delays disease onset and mortality in a transgenic model of ALS.
    Van Den Bosch L; Tilkin P; Lemmens G; Robberecht W
    Neuroreport; 2002 Jun; 13(8):1067-70. PubMed ID: 12060810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions with GluR1 AMPA receptors could influence the therapeutic usefulness of minocycline in ALS.
    Manev H; Manev R
    Amyotroph Lateral Scler; 2009; 10(5-6):416-7. PubMed ID: 19922133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovariectomy and 17beta-estradiol modulate disease progression of a mouse model of ALS.
    Groeneveld GJ; Van Muiswinkel FL; Sturkenboom JM; Wokke JH; Bär PR; Van den Berg LH
    Brain Res; 2004 Sep; 1021(1):128-31. PubMed ID: 15328040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies.
    Gurney ME
    J Neurol Sci; 1997 Oct; 152 Suppl 1():S67-73. PubMed ID: 9419057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.